DIRS.INFO The most relevant business & tech news

☆ FDA clears first digital treatment for depression, but experts caution that research is still early
▼ + stars: | 2024-04-02 | by ( Mira Cheng | ) edition.cnn.com time to read: +5 min

CNN —The US Food and Drug Administration is allowing the use of Rejoyn, the first prescription digital treatment for major depressive disorder. About 18% of American adults – more than 1 in 6 – say they are depressed or receiving treatment for depression, a 2023 Gallup report found. Rejoyn is designed to serve as an adjunct to antidepressants for these partial responders, according to the news release. They were assigned to use either the Rejoyn app or a sham app that gave memory tasks that did not involve cognitive-emotional training or cognitive behavioral therapy. There is also the question of how engaged patients will be with the app, Torous said.

Persons: Rejoyn, Dr, John Kraus, Otsuka, Brian Iacoviello, John Torous, Torous, ”, ” Otsuka, Sanjay Gupta, “, ” Torous Organizations: CNN, Food and Drug Administration, Otsuka Pharmaceutical, Therapeutics, Gallup, Research, Click Therapeutics, Digital Psychiatry, Beth Israel Deaconess Medical, FDA, ” Otsuka Pharmaceutical, CNN Health

☆ Stocks making the biggest moves premarket: Robinhood, GameStop, Merck and more
▼ + stars: | 2024-03-27 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Robinhood — Shares of the brokerage firm jumped more than 6% after unveiling its Robinhood Gold Card, a credit card where cash back can be deposited into a brokerage account. Concentrix — Shares slipped nearly 4% on the back of disappointing fiscal second-quarter earnings guidance. The customer experience technology company also reiterated its full-year outlook for 2024. In the prior session , the stock popped more than 15% on promising trial results for a weight loss pill. Trump Media & Technology Group — Shares of former President Donald Trump's social media company climbed nearly 14% after making its debut as a publicly traded company a day earlier.

Persons: Krispy, McDonald's, Morgan Stanley, Donald Trump's, — CNBC's Michelle Fox, Sarah Min, Jesse Pound Organizations: GameStop, Moderna, Blackstone Life Sciences, Viking Therapeutics, Deutsche Bank, Trump Media & Technology, Merck, Food and Drug Administration, FactSet

☆ Viking Therapeutics stock jumps more than 25% on promising weight loss pill data
▼ + stars: | 2024-03-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Viking Therapeutics shares jumped more than 25% on Tuesday after the company said its experimental weight loss pill showed positive results in a small study and will enter the next stage of development later this year. The study results add to the excitement around the drugmaker's prospects in the budding weight loss drug market. Based on Tuesday's results, Viking plans to start a phase two trial of its weight loss pill later this year. Weight loss for those patients ranged up to 3.6% higher than those who received a placebo. Viking CEO Brian Lian said during a conference call on Tuesday that it's unclear "how durable" the weight loss is.

Persons: Eli Lilly, Viking, Brian Lian Organizations: Viking Therapeutics, Novo Nordisk, Viking

☆ Viking jumped 25% on early weight loss pill data. We still prefer Eli Lilly
▼ + stars: | 2024-03-26 | by ( Jeff Marks | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Finally, Viking Therapeutics soared more than 25% after reporting encouraging Phase 1 results of its oral weight loss pill. The data showed up to 5.3% weight loss at 28 days. Its Phase 2 results up to 14.7% mean weight loss at 36 weeks. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Larry Fink, It's, Wedbush, Jim, Eli Lilly, Jim Cramer's Organizations: CNBC, BlackRock, Census Bureau, Social Security, Microsoft, Justice Department, Viking Therapeutics

☆ Stocks making the biggest moves midday: Krispy Kreme, Trump Media, McCormick and more
▼ + stars: | 2024-03-26 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

Krispy Kreme — Krispy Kreme popped nearly 30% and headed for its best day on record. Trump Media & Technology Group — Shares of former President Donald Trump's social media company surged 35% after it began trading on the Nasdaq . Trump Media completed its merger with shell company Digital World Acquisition Corp . McCormick — The stock jumped 10% after the spice maker topped earnings and revenue expectations for its fiscal first quarter. Reddit — Reddit popped about 15% as investors continued buying up the social media stock following its Thursday debut on the New York Stock Exchange .

Persons: Kreme, McDonald's, Donald Trump's, McCormick, Morgan Stanley, Alex Harring, Michelle Fox, Jesse Pound, Pia Singh Organizations: Trump Media & Technology, Nasdaq, Trump Media, Revenue, New York Stock Exchange, Viking Therapeutics, Seagate Technology, Micron Technology, Mizuho Securities, UPS —, UPS, JPMorgan Locations: FactSet

☆ This biotech startup is finding new cancer drugs with $75 million from General Catalyst. Here's the pitch deck Georgiamune used to raise its Series A.
▼ + stars: | 2024-03-26 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +4 min

Then, at the Georgia Cancer Center at Augusta University, he began the research that would eventually spin off into his first startup, Georgiamune. The same month, Georgiamune also got FDA clearance to begin human clinical trials for its first cancer drug candidate. Georgiamune's primary drug target works to solve a problem posed by another type of cancer drug on the market, called checkpoint inhibitors. For a Series A biotech startup, Georgiamune has an unusually extensive pipeline, with nine biological targets identified internally, all of which use different mechanisms of action than existing drugs. AdvertisementHere's the 21-slide pitch deck Georgiamune used to raise a $75 million Series A co-led by General Catalyst.

Persons: —, Samir Khleif, King, Khleif, Catalyst, CJNV BioVenture, Georgiamune, doesn't, Amy Abernethy, Khleif's, General Catalyst Organizations: Service, King Hussein Cancer Center, Georgia Cancer Center, Augusta University, Business, Parker Institute for Cancer, Mubadala, Alexandria Venture Investments, Catalio Capital Management, Verition Fund Management, Bicara Therapeutics, Therapeutics, General Locations: Jordan, Verily

☆ Amgen wants in on the booming weight loss drug market — and it's taking a different approach
▼ + stars: | 2024-03-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +9 min

Mario Tama | Getty ImagesAmgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug. It's too early to say how competitive Amgen will be in the budding weight loss drug space, which Novo Nordisk and Eli Lilly have so far dominated. Goldman Sachs also projects that between 10 million and 70 million Americans will be taking weight loss drugs by 2028. The sustained weight loss in Amgen's study appears to contrast with results seen in clinical trials on Zepbound and Wegovy. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: Mario Tama, Eli Lilly, Goldman Sachs, Zepbound, Eli Lilly's, Amgen's MartiTide, Caroline Apovian, Apovian, Joe Buglewicz, MariTide, Holly Lofton, Eli Lilly’s, Brendan McDermid, Reuters Amgen's, William Blair, Matt Phipps, Phipps Organizations: Getty, Novo Nordisk, Pfizer, Viking Therapeutics, Therapeutics, Zealand Pharma, Boehringer, Center, Weight Management, Wellness, Brigham, Women's, Washington Post, NYU Langone Health, Reuters, William Blair & Company, CNBC Locations: Thousand Oaks , California, Oaks , California, Novo, New York City, U.S

☆ Jefferies likes these dividend-growing stocks for 2024
▼ + stars: | 2024-03-18 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Investors searching for income could be well-rewarded by turning to dividend-growing stocks, according to Jefferies. "Consensus expects USA dividend growth to accelerate from 3.9% for 2023 to 6.2% for 2024, along with positive revisions," Peramunetilleke wrote in a note Wednesday. JPMorgan Chase , which has a 2.3% 12-month forward dividend yield, is the largest name on the list. AbbVie also made the list with a 12-month forward dividend of 3.5%. McDonald's , which has a 2.4% 12-month forward dividend, also made the cut.

Persons: Peramunetilleke, Jefferies, AbbVie, Robert Michael Organizations: Jefferies, JPMorgan Chase, Therapeutics

☆ This overlooked corner of women's health could be a $350 billion market opportunity
▼ + stars: | 2024-03-15 | by ( Michelle Fox | ) www.cnbc.com time to read: +5 min

The management consultant estimates the global market potential to treat symptoms ranges from $120 billion to as much as $350 billion globally. "That would apply to women's health in general, and then specifically and acutely to menopause in particular." From 2002 to 2009, hormone therapy claims were reduced by more than 70%, a 2012 study showed. The clinical-stage biopharmaceutical company, which focuses on women's health, has an intravaginal ring hormone therapy that is set to progress to a single Phase 3 study. Last May, the Food and Drug Administration approved Tokyo-based Astellas Pharma's Veozah, also known as fezolinetant, to treat hot flashes.

Persons: Drew Barrymore, Naomi Watts, Anna Pione, Stephanie Faubion, Faubion, Karen Adams, Jefferies, Kaumil Gajrawala, Bayer, Progyny, Sasha Kelemen Organizations: McKinsey, Health, Mayo Clinic Center, Women's Health, Stanford University, Pfizer, Dare, Food and Drug Administration, Vistagen Therapeutics, Gennev, Midi Health, Leerink Partners Locations: U.S, Tokyo

☆ Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors
▼ + stars: | 2024-03-13 | by ( Brenda Goodman | ) edition.cnn.com time to read: +10 min

Only 3% to 5% of people who are diagnosed with this type of brain tumor will be alive three years later. Now, an experimental therapy that reprograms a person’s own immune cells to attack these tumors is showing some exciting promise. Doctors first harvested immune fighters called T-cells from his blood and then genetically modified them in a lab so they’d recognize and bind to specific proteins on the surface of the brain tumor cells. After a single 10-milliliter infusion of about 10 million CAR-T cells, Fraser’s tumor began to shrink. Three-quarters of the participants had had their brain tumors come back at least twice.

Persons: ”, Otis Brawley, –, they’ll, ” Brawley, Tom Fraser, Brigham, Debbie Fraser, Fraser, He’s, Marcela Maus, ” Fraser, Maus, “, ” Maus, Christine Brown, ’ Brown, ” Brown, hasn’t, Brown, Dr, Donald O’Rourke, “ They’re, O’Rourke, ” O’Rourke, Sanjay Gupta, you’re, they’re, it’s Organizations: CNN, Johns Hopkins University, American Cancer Society, City of Hope Cancer Center, University of Pennsylvania, Massachusetts General, Mass, New England, of Medicine, Doctors, Mass General Cancer Center, Tv3, Cell Therapeutics Research, of, Nature, Penn, Excellence, University of Pennsylvania Perlman School of Medicine, CNN Health Locations: City, Duarte , California, Massachusetts, Rochester , New York, Boston, of Hope, Hope

☆ 4 economic reports the market cares about most next week, including a fresh look at inflation
▼ + stars: | 2024-03-09 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

Within the Club, we heard this week from Foot Locker on Wednesday, then from Costco and Broadcom on Thursday. The big economic data drop of the week arrived Friday with February's nonfarm payrolls report . The center of attention is Tuesday's February consumer price index report . On Thursday, the February produce price index is due out. ET: Producer Price Index 8:30 a.m.

Persons: FactSet, Locker, Foot Locker, February's nonfarm, Jerome Powell, he's, we'll, MANU, LEN, Jim Cramer's, Jim Cramer, Jim, Mostafa Bassim Organizations: Nasdaq, Dow Jones Industrial, Costco, Broadcom, Commerce, Federal, PPI, Ballard Power Systems, Fortrea Holdings, Casey's, Vail Resorts, MTN, Daniels, Midland, Kohl's Corporation, Kanzhun, Game Technology, Manchester United, Blade Air Mobility, Clover Health, Beauty Health, Energy Vault Holdings, PHX Minerals, Guild Holdings, Finance, Heron Therapeutics, ZIM Integrated Shipping Services, Arcos Dorados Holdings, ARCO, Petco, Wellness Company, Farms, Sonoma, WSM, ESS Tech, DICK'S Sporting, Inc, Futu Holdings, Bear, Autolus Therapeutics, III Apparel, Solo Brands, Weibo Corporation, Embraer, CNBC, Washington DC, Anadolu, Getty Locations: U.S, Asana, ASAN, Williams, Washington, United States

☆ Single dose of LSD provides immediate, lasting anxiety relief, study says
▼ + stars: | 2024-03-07 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +8 min

CNN —A clinical trial’s encouraging results won US Food and Drug Administration breakthrough therapy status for an LSD formulation to treat generalized anxiety disorder, Mind Medicine Inc. announced Thursday. Generalized anxiety order is characterized by excessive, ongoing thoughts that are difficult to control and interfere with day-to-day activities. Anxiety is one of the most common mental disorders in the US, according to the Anxiety and Depression Association of America. The MM120 study, however, was accomplished without the use of psychotherapy during the session. So that’s a critical difference.”Most adverse effects in the study were rated as mild to moderate by participants, occurring mostly on the day of the study, Karlin said.

Persons: “, ”, Daniel Karlin, MindMed’s MM120, ” Karlin, buspirone —, Karlin, David Nutt, Nutt, Dr, Gabriella Gobbi, Timothy Leary, Richard Alpert, Eddie Adams, Leary, Richard Nixon Organizations: CNN, US Food and Drug Administration, Medicine Inc, Tufts University School of Medicine, FDA, Depression Association of America, Unit, Imperial College London’s, McGill University Health Centre, Canada, Therapeutics, Mental Health, Harvard University, Harvard, League for Spiritual, Woodstock Locations: Boston, United States, Montreal, New York, Vietnam

Despite a challenging fundraising environment, women-led venture capital funds made gains in 2023. According to research by Venture Capital Journal, women-led funds' share of total fundraising increased to about 3% of the $107 billion raised last year by venture funds worldwide, up from less than 2% of the 2022 total. While it's a small fraction of the total pool, venture capital funding in the U.S. for companies founded by women has been trending up in recent years. The upswing has had some help from the creation of incubators for women founders, more new companies founded by women and more venture capital funds focused on underrepresented founders. Portfolia creates and manages about 16 venture funds designed for individual investors who want to invest in a portfolio of mostly women-led startups and want to learn more about venture investing.

Persons: Trish Costello, Portfolia, Costello, Elizabeth Clayborne, Steve Washington, Clayborne, wouldn't Organizations: Venture Capital Journal, YourChoice Therapeutics, CNBC Locations: U.S

☆ Morgan Stanley says M&A will rebound and these stocks have an 'elevated likelihood' of a takeover
▼ + stars: | 2024-03-05 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

Global mergers and acquisition activity will soar this year, and several names could benefit from the comeback, according to Morgan Stanley. The firm expects global M & A volume activity to rise by 50% this year compared to 2023. "We believe that a cyclical and structural rebound in M & A is coming," Morgan Stanley said in a note titled "Stocks with Elevated Likelihood of Receiving an Offer," which was released Monday. Morgan Stanley pointed out that 2021 to 2023 could have seen a drop of activity worth between $4 trillion and $11 trillion. Morgan Stanley said it has no information about M & A activity involving the companies.

Persons: Morgan Stanley, Morgan, Stephen Ju, Morgan Stanley's Organizations: Health, Sarepta Therapeutics, Tenet Healthcare, Analysts, BMO Capital Markets, UBS, Hertz Global Holdings Locations: Europe

☆ Jim Cramer says he really wants 'everyone to own' this nimble oil and energy stock
▼ + stars: | 2024-03-04 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Jim Cramer said the stock is a must-own tied to energy and oil. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Dow, Eaton, Locker, Jerome Powell, Jim, Thomas Jorden, Eli Lilly, Lilly, Jim Cramer's Organizations: CNBC, Nasdaq, Nvidia, Broadcom, Costco, Capitol, Coterra Energy, Management, Wall, UBS, Club, Therapeutics Locations: AVGO, FL

☆ Morgan Stanley thinks this little-known autoimmune biotech stock can surge more than 40%
▼ + stars: | 2024-03-04 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Newly public biotech Kyverna Therapeutics could be a blockbuster cell therapy developer for autoimmune disease, according to Morgan Stanley. The stock opened at $34.25, above the initial public offering price of $22 per share, and closed Friday at $27.75. Although the data from KYV-101 is limited, Ulz wrote that he's "highly encouraged given promising results across multiple indications, multiple sites, and in challenging patients." The analyst pointed out that cell therapies have "meaningfully improved" the treatment of B-cell cancers and that multiple therapies are currently approved, increasing the therapies' potential to treat autoimmune diseases. Ingenui-T is a next-generation process in preclinical development for manufacturing autologous anti-CD19 CAR T-cell therapy, and uses the same CAR construct as KYV-101, Kyverna said.

Persons: Morgan Stanley, Michael Ulz, Kyverna, Ulz Organizations: Therapeutics, Nasdaq, autoimmunity Locations: KYV, Kyverna

☆ Here are Monday's biggest analyst calls: Nvidia, Apple, Super Micro, Eli Lilly, Lyft, DoorDash, Disney & more
▼ + stars: | 2024-03-04 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

UBS upgrades Norfolk Southern to buy from neutral UBS said it sees margin improvement for the railroad. Goldman Sachs initiates Super Micro as neutral Goldman said the stock is an "AI winner" but that valuation is full right now. UBS reiterates Eli Lilly as buy UBS raised its price target on the stock to $910 per share from $810. UBS reiterates Nvidia as buy UBS said it's sticking with its buy rating after a series of investor meetings with the company." Argus upgrades New York Times to buy from neutral Argus said it sees revenue growth for the newspaper company. "

Persons: Morgan Stanley, Disney, Piper Sandler, Piper, Guggenheim, Baird, SQSP, Goldman Sachs, Goldman, Bernstein, Tesla, underperform Bernstein, Eli Lilly, Wells, Melius, Citi downgrades Ferrari, Jefferies, Evercore, it's, Rosenblatt, Snowflake, Slootman's Organizations: BROS, Guggenheim, GSK, UBS, Norfolk Southern, Micro, JPMorgan, Nvidia, Kyverna Therapeutics, FLT, UDR, Conservative, America Health, RBC, Apple, Citi, Ferrari, Jefferies, BP, Barclays, Barclays downgrades, ISI, Toast Inc, Bank of America, Ball Corp, of America, Broadcom, New York Times Locations: Norfolk, China, New

☆ Stocks making the biggest moves midday: Macy's, Super Micro Computer, Lyft, DoorDash and more
▼ + stars: | 2024-03-04 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Super Micro Computer , Deckers Outdoor — The technology firm and athletic footwear designer respectively popped 27% and nearly 3% after S & P Dow Jones Indices announced Friday that the two stocks would be added to the S & P 500 on March 18. Super Micro Computer and Deckers Outdoor will replace Zions Bancorpation and Whirlpool , which will move to the S & P MidCap 400 Index. Macy's — Shares skyrocketed 16% after Arkhouse Management said it and Brigade Capital Management have raised their offer for the department store . DoorDash — Shares jumped more than 5% after RBC upgraded the food delivery company to outperform from sector perform. Lyft — The ride-sharing platform added 6% after RBC upgraded the stock to an outperform rating from sector perform.

Persons: Dow, Zions, —, Lyft, Morgan Stanley, Li, Piper Sandler, Ford, CNBC's Michelle Fox, Alexander Harring, Hakyung Kim, Tanaya Macheel, Yun Li, Jesse Pound, Samantha Subin Organizations: Micro Computer, Dow Jones, Whirlpool, Arkhouse Management, Brigade Capital Management, Apple, European, Miners, Marathon Digital, Cipher Mining, Iris Energy, RBC, Kyverna Therapeutics, Wells, JPMorgan, Ferrari —, Citi, Li Auto, Dutch Bros, American Airlines —, Max Locations: Wells Fargo

☆ Stocks making the biggest moves premarket: Super Micro Computer, Deckers Outdoor, Macy's and more
▼ + stars: | 2024-03-04 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

Super Micro Computer , Deckers Outdoor — Shares of Super Micro Computer and Deckers Outdoor jumped 12% and 5%, respectively, after S & P Dow Jones Indices said Friday the two companies would be added to the S & P 500 later this month. They will replace Whirlpool and Zion Bancorp, which will move to the S & P MidCap 400 index as of the March 18 open. Macy's — Macy's stock skyrocketed nearly 17% after Arkhouse Management upped its buyout offer for the department store chain to $24 from $21 a share, or about $6.6 billion. Crypto stocks – Companies whose performance is tied to the price of bitcoin rose in premarket trading after the cryptocurrency touched another two-year high . Spirit AeroSystems , Boeing — Shares of the fuselage maker rose nearly 3%.

Persons: Dow, CleanSpark, AeroSystems, Lyft, Morgan Stanley, Li Auto, Piper Sandler, Brian Mullan, — CNBC's Lisa Han, Fred Imbert, Tanaya, Hakyung Kim, Jesse Pound, Michelle Fox Organizations: Micro Computer, Dow Jones, Whirlpool, Zion Bancorp, Arkhouse Management, Apple, European Commission, Marathon, Iris Energy, RBC, Boeing —, Boeing, Max, —, Citi, Li Auto, Li, Mobile

☆ Viking Therapeutics emerges as a strong weight loss drug player — or takeover target
▼ + stars: | 2024-03-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

In this article VKTX Follow your favorite stocks CREATE FREE ACCOUNTCr | Istock | Getty ImagesBiotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Their treatments sparked the weight loss drug industry gold rush over the past year despite their hefty price tags and barriers to insurance coverage. It's too early to say whether Viking's drug could have an edge over existing or developing weight loss treatments. The pharmaceutical giant could also launch a slate of other weight loss treatments over the next few years that may have advantages over Zepbound, whether they offer more weight loss or convenience. That could give Viking the commercial and manufacturing capabilities needed to compete in the weight loss drug market.

Persons: Eli Lilly, Eli Lilly's Zepbound, Viking, Goldman Sachs, Eli Lilly’s, Brendan Mcdermid, GLP, Brian Lian, William Blair, Andy Hsieh, Hsieh, Eli Lilly's, Jefferies, Akash Tewari, doesn't, Mike Segar, Lian, William Blair's Hsieh, Oppenheimer, Jay Olson Organizations: Getty Images Biotech, Viking Therapeutics, Novo Nordisk, Reuters, Viking, Novo, U.S . Food, Drug Administration, Company, Deutsche Bank, CNBC Locations: New York City, Branchburg , New Jersey

☆ Crispr Therapeutics CEO: Science in gene editing is moving at breakneck speed
▼ + stars: | 2024-02-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCrispr Therapeutics CEO: Science in gene editing is moving at breakneck speedSamarth Kulkarni, Crispr Therapeutics CEO, joins 'Power Lunch' to discuss the hurdles to getting rare disease drugs through regulation, what consumers can look forward to in gene editing, and much more.

Persons: Samarth Kulkarni Organizations: Crispr, Crispr Therapeutics

☆ Here is Eli Lilly's competitive edge in GLP-1 obesity drugs and Abbott's secondary play
▼ + stars: | 2024-02-29 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.

Persons: Jim Cramer, Dow, Jim, Chris Danely, Cramer, Eaton, Eli Lilly, Lilly, Jim Cramer's Organizations: CNBC, Dow, Nasdaq, Semiconductor, Citi, Broadcom, Nvidia, Devices, Micron, Dell Technologies, Autodesk, Novo Nordisk, Abbott Laboratories, Novo, Viking, Jim Cramer's Charitable

☆ Viking Therapeutics' weight loss drug showed faster results in clinical trials than Ozempic or Wegovy. Here's how it works.
▼ + stars: | 2024-02-28 | by ( ) www.businessinsider.com time to read: +3 min

Biotech company Viking Therapeutics saw stock prices double after a report on weight loss drug VK2735. The new drug could lead to even more weight loss at a faster pace than Ozempic or Mounjaro. Viking Therapeutics, a small California-based biotech company, shared the topline results from a mid-stage trial of its drug VK2735 on February 27. AdvertisementHowever, the early results of clinical trials suggest it could be on par to offer even more weight loss in less time than its competitors. How Viking Therapeutics' weight-loss drug worksVK2735 mimics two hormones that affect weight control.

Persons: —, Eli Lilly, GIP, VK2735 Organizations: Biotech, Viking Therapeutics, Service, Novo Nordisk, Washington Post, Therapeutics, Viking Locations: California

☆ One down one to go — what we learned from TJX's great quarter and hope to hear from Salesforce
▼ + stars: | 2024-02-28 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Eli Lilly shares fell 1% on Wednesday following a similar drop in the prior session. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Salesforce, Jim, Let's, Eli Lilly, Jim Cramer's Organizations: CNBC, TJX Companies, Management, Therapeutics Locations: GLP

☆ Cramer’s Stop Trading: Viking Therapeutics
▼ + stars: | 2024-02-27 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCramer’s Stop Trading: Viking TherapeuticsCNBC’s Jim Cramer explains why he is keeping an eye on shares of Viking Therapeutics.

Persons: Jim Cramer Organizations: Therapeutics, Viking Therapeutics

Search resuls for: "THERAPEUTICS"

25 mentions found